Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia

　　1.Mechanism of Action:Multi-Pathway Regulation via Physiological Hypoxia Mimicry

　　Vadadustat selectively inhibits prolyl hydroxylase domain proteins(PHD1,PHD2,and PHD3),blocking the hydroxylation-dependent degradation of hypoxia-inducible factor-alpha(HIF-α)subunits.This allows HIF-αto stabilize and accumulate under normoxic conditions,translocate to the nucleus,and activate downstream target gene transcription.The resulting therapeutic effects are multifaceted:upregulation of endogenous erythropoietin(EPO)synthesis and secretion to stimulate erythropoiesis,and concurrent upregulation of iron metabolism-related genes including transferrin,transferrin receptor,and divalent metal transporter 1,thereby improving functional iron deficiency.Compared to injectable erythropoiesis-stimulating agents(ESAs),vadadustat achieves a more physiologically balanced EPO regulation through oral administration,avoiding the potential risks associated with supraphysiological exogenous EPO concentrations.

　　2.Core Efficacy Evidence in Dialysis-Dependent Patients

　　The efficacy of vadadustat in dialysis-dependent CKD(DD-CKD)anemia has been robustly validated in multiple large-scale Phase III randomized controlled trials.The INNO2VATE program demonstrated that vadadustat effectively raises hemoglobin levels from baseline and maintains them within the target range of 10 to 12 g/dL,meeting non-inferiority criteria versus standard ESA therapy including darbepoetin alfa.During the maintenance phase,most patients achieved stable hemoglobin levels with infrequent dose adjustments.The FO2CUS trial post-hoc analysis presented at the 2026 National Kidney Foundation Spring Clinical Meeting further confirmed that vadadustat administered three times weekly achieved consistent hemoglobin control regardless of baseline ESA dose,while significantly reducing red blood cell transfusion requirements.

　　3.Efficacy and Applicability in Non-Dialysis-Dependent Patients

　　In non-dialysis-dependent CKD(NDD-CKD)anemia patients,the PRO2TECT program evaluated the efficacy and safety of vadadustat.Results demonstrated effective anemia correction with hemoglobin levels reaching and maintaining the target range,reducing dependence on red blood cell transfusions.The moderate rate of hemoglobin rise helps mitigate hemodynamic fluctuation risks associated with rapid anemia correction.It should be noted that the approved indication for vadadustat in certain regulatory jurisdictions is primarily limited to dialysis-dependent patients,and use in non-dialysis patients requires individualized assessment based on regional approval status and clinical guidelines.

　　4.Synergistic Optimization of Iron Metabolism

　　Beyond anemia correction,vadadustat exerts beneficial synergistic effects on iron metabolism.Clinical studies observed a progressive decline in serum ferritin levels among vadadustat-treated patients,while transferrin saturation remained relatively stable,indicating more effective mobilization and utilization of stored iron for erythropoiesis.This characteristic reduces the need for intravenous iron supplementation in some patients,decreasing the inconvenience and potential infection risks associated with frequent venous access—a practical benefit for long-term anemia management.

　　5.Blood Pressure and Cardiovascular Safety Assessment

　　Blood pressure management is a critical consideration in CKD anemia therapy.Unlike ESAs,particularly at high doses,which may elevate blood pressure,vadadustat has not demonstrated a significant trend toward increased hypertension risk in clinical studies.Some studies even observed a mild blood pressure-lowering effect,which may confer additional clinical benefit in CKD patients with comorbid hypertension.Regarding major adverse cardiovascular events(MACE),data from dialysis-dependent patients indicate comparable cardiovascular risk between vadadustat and ESAs without additional safety signals.However,long-term cardiovascular safety data in non-dialysis populations require continued accumulation and monitoring.

　　6.Dosing Regimen and Patient Adherence Advantages

　　The recommended starting dose of vadadustat is 300 mg orally once daily,with flexible adjustment within the range of 150 to 600 mg daily based on hemoglobin response.Once-daily oral administration offers substantial convenience advantages over ESA regimens requiring subcutaneous or intravenous injections multiple times per week,reducing the frequency of healthcare facility visits.Clinical trial data demonstrate good patient adherence with oral dosing,with lower missed-dose rates compared to injectable regimens.For CKD patients requiring long-term anemia management,this convenience translates into more stable therapeutic exposure and more reliable efficacy maintenance.

　　7.Special Populations and Efficacy Predictors

　　Subgroup analyses in elderly CKD patients and those with comorbid diabetes showed consistent efficacy with the overall population,without significant efficacy attenuation.Notably,vadadustat maintains effective stimulation of endogenous EPO production even in patients with elevated baseline inflammatory markers,a property that distinguishes it from certain ESAs that are sensitive to microinflammatory states.Regarding efficacy prediction,patients with lower baseline C-reactive protein levels,moderate ferritin ranges,and better residual renal function tend to achieve superior treatment responses.These factors can be integrated in clinical practice to preliminarily predict individual treatment trajectories and guide personalized strategies.

　　8.Clinical Positioning and Summary

　　Based on existing global multicenter clinical evidence,vadadustat provides an effective and convenient oral treatment option for CKD-related anemia.Its core advantages include:physiological EPO regulation with efficacy comparable to ESAs;synergistic improvement in iron metabolism reducing intravenous iron requirements;oral administration enhancing adherence;and a neutral or slightly favorable blood pressure profile.The drug is particularly suitable for dialysis-dependent CKD anemia patients with suboptimal ESA response,preference to avoid long-term injections,or comorbid functional iron deficiency.As real-world data continue to accumulate,the therapeutic value of vadadustat in broader patient populations is expected to be further validated.